ALZHEIMER'S IMMUNOTHERAPY IN A PRIMATE MODEL OF CEREBRAL AMYLOID ANGIOPATHY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目正在调查A免疫在松鼠猴身上的效果，松鼠猴是一种随着年龄增长而患上显著血管淀粉样变性的物种。我们已经证明，对老年松鼠猴子进行针对A蛋白的短期免疫是安全的，并且能够诱导显著的抗体形成。A蛋白对阿尔茨海默病的发展至关重要。在免疫11周后，也有有限血管病变的病理证据，证实了松鼠猴是测试阿尔茨海默病免疫疗法安全性和有效性的良好模型。本研究已经开始了长期免疫，以更接近于人类临床使用的免疫疗法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is investigating the effects of A¿-immunization in the squirrel monkey, a species that develops significant vascular ¿-amyloidosis with age. We have shown that short-term immunization of older squirrel monkeys against the A¿ protein, which is critical to the development of Alzheimer's disease, is safe and is able to induce significant antibody formation. There is also pathological evidence of limited vasculopathy after 11 weeks of immunization, confirming that squirrel monkeys are a good model for testing the safety and efficacy of immunotherapy for Alzheimer's disease. The present study has begun long-term immunization to more closely mimic human clinical use of immunization therapy.